At Alnylam, we believe that making history means advancing groundbreaking science while shaping a healthier, more equitable, and sustainable future for all," said Yvonne Greenstreet, M.D., Chief ...

An Alnylam spokesperson said the company was evaluating its options and may appeal. A BioNTech spokesperson said the filing "confirms Pfizer's and BioNTech's position that we do not infringe any ...

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Alnylam Pharmaceuticals Inc. (ALNY) on Thursday reported a loss of $57.5 million in its first quarter. The Cambridge, Massachusetts-based ...

Alnylam's Amvuttra and partner Sanofi's fitusiran have PDUFA dates with the FDA next month, and approvals should create new revenue sources for the company. Alnylam's 2025 guidance for the TTR ...

Reports Q4 revenue $593.17M, consensus $580.62M. “2024 was another year of impressive execution for Alnylam (ALNY), generating product revenues of over $1.6 billion, reflecting growth of 33% ...

Oct 2 (Reuters) - Alnylam Pharmaceuticals (ALNY.O), opens new tab admitted defeat, for now, in a lawsuit in Delaware federal court that accused Moderna's (MRNA.O), opens new tab blockbuster COVID ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming TTR Investor Day event on ...

Getty Images Alnylam Pharmaceuticals announced a Phase-3 study of its treatment for a rare heart condition showed a significant reduction in deaths and recurrent cardiovascular events. The ...

Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings within the last quarter: According to 20 analyst offering 12-month price targets in the last 3 months, Alnylam ...